Drs. Keith Kerr and Sanja Dacic shared findings from the IASLC Pathology Committee, which is investigating how to best assess pathologic response to neoadjuvant immunotherapy in lung cancer. Read more
During WCLC 2023, Dr. Yan Zhang presented findings that she says support the inclusion of factors such as early menarche and early menopause in lung cancer screening programs. Read more
Drs. Wendy Cooper, Melissa Culligan, And Navneet Singh concluded the session with talks on the future of pathology, enhancing the patient experience, and accurate staging in lung cancer. Read more
The challenge, Step It Up for Research, helped WCLC 23 attendees stay active during the meeting while raising money to support the IASLC Foundation, which provides grants for research, education, and other scientific initiatives. Read more
IASLC Staging and Prognostic Factors Committee Chair Dr. Hisao Asamura and Drs. Valerie Rusch and Enrico Ruffini summarized the data and recommendations in lung cancer, mesothelioma, and thymic cancer. Read more
Dr. Tetsuya Mitsudomi, who presented the data at WCLC 2023, said regardless of disease stage, the addition of perioperative durvalumab did not adversely impact the feasibility, type, approach, or timing of surgery for participants in the trial. Read more
Drs. Mariam Jamal-Hanjani, Alan Sihoe, Anil Tibdewal, and Ross Soo discussed challenges and strategies across the lung cancer spectrum—from early-stage to oligometastatic and advanced disease. Read more
Honorees Drs. Jessica Donington, Rafal Dziadziuszko, and Jie Wang presented thought-provoking talks on return to treatment after surgery, radiation oncology in Poland, and biomarkers in small cell lung cancer. Read more
The IASLC Academy’s 2023 cohort spent months leading up to WCLC 2023 crafting case summaries in hopes of winning a spot in the association’s first case-based simulation course. Read more